Here is a success story that demonstrates how CSI can support your clinical trial supplies. CSI managed to compress six months of...

Innovation in oncology drug development is granting cancer patients access to life-changing therapies. The industry continues to conduct...

How CSI’s scientific insight delivered an agile sourcing model and substantial cost savings for a listed biotechnology company’s global...

Unwrap CSI's Twelve Case Studies of Christmas 2020 has been a challenging year, with product shortages, borders closing, more...

Oncology products monopolise the list of best-selling drugs. With a huge range of indications that is only growing, therapies become more specific to tumour or cell pathologies and increasing patient numbers. Several oncology products now have ‘blockbuster’ status where sales exceed $1 billion annually. This is relevant for clinical trials as more regulators require evidence of efficacy in comparison to the standard of care, which is likely to be one of the blockbuster produc

How CSI leveraged relationships with multiple manufacturers to urgently supply large quantities of a generic drug to a global Phase 3...